Genmab has made the strategic decision to consolidate its manufacturing operations and is offering its Brooklyn Park, Minnesota, cell culture manufacturing site for sale. This 36-acre site contains a 215,000 SF mammalian cell culture manufacturing facility with 22,000 Liters of capacity. PharmaBioSource Realty, LLC, has been exclusively retained by Genmab to market the facility.

The Opportunity:

The site is located approximately 15 miles from Minneapolis, a major city in the mid-Western United States. The state-of-the-art bulk biologics manufacturing facility was constructed in 2004 and represents an investment of $240M. The facility is designed to produce monoclonal antibodies and may also support the production of cell culture-based vaccines. Acquisition of the Genmab site would provide:

- Access to a new, state-of-the-art cell culture facility for the manufacture of therapeutic biologic products.
- The opportunity to acquire biologics capacity for simultaneous multi-product production.
- The potential to utilize the product development laboratories to develop new therapeutic biologics and for technology transfer purposes.
- Access to an experienced technical team and a skilled Life Sciences work force.
- Access to a business-friendly environment with significant Life Sciences manufacturing and research and development incentives.
- Excellent site infrastructure with opportunities for expansion including installation of a fill/finish line.
Highlights of the facilities include:

- Flexible, modern batch automated bulk biologics cell culture manufacturing facility suited for the production of monoclonal antibodies and vaccines:
  - Two segregated manufacturing trains each with 1,000L and 10,000L bioreactors.
  - Flexibility to operate the 1,000L reactors at 400L and the 10,000L reactors at 5,000L.
  - Fed batch cell culture process.

- Laboratory, office, warehouse and support facilities:
  - Modern, well equipped Quality and Metrology laboratories.
  - New warehouse facilities and extensive utility infrastructure and administrative support facilities.

Interested parties should contact PharmaBioSource Realty, LLC, the exclusive listing agent for this opportunity, for more information regarding an acquisition of this Minneapolis-based cell culture manufacturing facility from Genmab. Additional information is also available on our web site:

www.genmab-facility.com

For further information, please contact:

**SEAN P. MCKEE**  
Technical Information  
Cell: 484.686.0123  
smckee@pharmabiosource.com

**JOE TARANTINO**  
Real Estate  
Phone: 610.293.0900  
jtarantino@pharmabiosource.com

No representation or warranty, express or implied, is given by Genmab, PharmaBioSource Realty, their respective advisers or any of their respective directors or employees or any other person as to the accuracy or completeness of the contents of this summary information. The only representations and warranties that will be made are those that may eventually be included in a definitive agreement to the proposed sale, if any. Neither this summary nor any of the information contained in it shall form the basis of any contract for the sale of the facility or any part of the facility or assets, nor does it constitute an offer, invitation or inducement to purchase or acquire any shares or assets in the facility or any interest in it.